{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:46:03Z","timestamp":1788608763340,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1002\/jps.24421","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T02:07:20Z","timestamp":1426558040000},"page":"1909-1918","source":"Crossref","is-referenced-by-count":17,"title":["14 N Nuclear Quadrupole Resonance Study of Piroxicam: Confirmation of New Polymorphic Form V"],"prefix":"10.1016","volume":"104","author":[{"given":"Zoran","family":"Lavri\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janez","family":"Pirnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Lu\u017enik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uro\u0161","family":"Puc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvonko","family":"Trontelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stane","family":"Sr\u010di\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1002\/jps.24421_bb0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1023\/A:1016241927429","article-title":"Pharmaceutical solids: A strategic approach to regulatory considerations","volume":"12","author":"Byrn","year":"1995","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1002\/jps.24421_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2007.04.021","article-title":"A material science perspective of pharmaceutical solids","volume":"339","author":"Cui","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.24421_bb0015","series-title":"Handbook of modern pharmaceutical analysis","first-page":"598","author":"Ahuja","year":"2011"},{"issue":"8","key":"10.1002\/jps.24421_bb0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/jps.2600580802","article-title":"Pharmaceutical applications of polymorphism","volume":"58","author":"Haleblian","year":"1969","journal-title":"J Pharm Sci"},{"issue":"3-4","key":"10.1002\/jps.24421_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF01197379","article-title":"On the polymorphism of pharmaceuticals and other molecular crystals I","volume":"72","author":"Burger","year":"1979","journal-title":"Mikrochim Acta"},{"issue":"3","key":"10.1002\/jps.24421_bb0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.addr.2003.10.008","article-title":"Drug polymorphism and dosage form design: A practical perspective","volume":"56","author":"Singhal","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1002\/jps.24421_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jps.22788","article-title":"Polymorphism and solvatomorphism 2010","volume":"101","author":"Brittain","year":"2012","journal-title":"J Pharm Sci"},{"issue":"01","key":"10.1002\/jps.24421_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1017\/S0885715600010757","article-title":"Quantitation of crystallinity in substantially amorphous pharmaceuticals and study of crystallization kinetics by X-ray powder diffractometry","volume":"15","author":"Surana","year":"2000","journal-title":"Powder Diffr"},{"issue":"9","key":"10.1002\/jps.24421_bb0045","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/1521-3773(20010504)40:9<1626::AID-ANIE16260>3.0.CO;2-7","article-title":"Contemporary advances in the use of powder X-ray diffraction for structure determination","volume":"40","author":"Harris","year":"2001","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"10.1002\/jps.24421_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0169-409X(01)00099-0","article-title":"Characterization of the solid state: Quantitative issues","volume":"48","author":"Stephenson","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"10.1002\/jps.24421_bb0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1359-6446(03)02832-0","article-title":"Solid-state analysis of the active pharmaceutical ingredient in drug products","volume":"8","author":"Newman","year":"2003","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1002\/jps.24421_bb0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10973-006-7962-y","article-title":"Comparison of quantitative methods for analysis of polyphasic pharmaceuticals","volume":"89","author":"Giron","year":"2007","journal-title":"J Therm Anal Calorim"},{"issue":"1","key":"10.1002\/jps.24421_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0169-409X(01)00101-6","article-title":"Characterization of the solid-state: Spectroscopic techniques","volume":"48","author":"Bugay","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"13","key":"10.1002\/jps.24421_bb0070","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1021\/ac0503658","article-title":"Potential of nuclear quadrupole resonance in pharmaceutical analysis","volume":"77","author":"Balchin","year":"2005","journal-title":"Anal Chem"},{"issue":"1","key":"10.1002\/jps.24421_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2005.04.015","article-title":"Utilization of pure nuclear quadrupole resonance spectroscopy for the study of pharmaceutical crystal forms","volume":"298","author":"P\u00e9rez","year":"2005","journal-title":"Int J Pharm"},{"issue":"1\u20133","key":"10.1002\/jps.24421_bb0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.chemphys.2009.09.011","article-title":"14N NQR in the tetrazole family","volume":"364","author":"Pirnat","year":"2009","journal-title":"Chem Phys"},{"issue":"12","key":"10.1002\/jps.24421_bb0085","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.22186","article-title":"Application of 14N NQR to the study of piroxicam polymorphism","volume":"99","author":"Lavri\u010d","year":"2010","journal-title":"J Pharm Sci"},{"issue":"45","key":"10.1002\/jps.24421_bb0090","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1021\/jp105449w","article-title":"14N NQR study of polymorphism and hydrogen bonding in molecular complex isonicotinamide-oxalic acid (2:1)","volume":"114","author":"Seliger","year":"2010","journal-title":"J Phys Chem A"},{"key":"10.1002\/jps.24421_bb0095","article-title":"Nuclear quadrupole resonance spectroscopy","volume":"223","author":"Das","year":"1958","journal-title":"New York: Academic Press, pp ix"},{"key":"10.1002\/jps.24421_bb0100","series-title":"Nuclear quadrupole coupling constants","first-page":"360","author":"Lucken","year":"1969"},{"key":"10.1002\/jps.24421_bb0105","series-title":"Nuclear quadrupole resonance spectroscopy data","year":"1997"},{"issue":"5","key":"10.1002\/jps.24421_bb0110","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/ac303267v","article-title":"Nitrogen-14 nuclear quadrupole resonance spectroscopy: A promising analytical methodology for medicines authentication and counterfeit antimalarial analysis","volume":"85","author":"Barras","year":"2013","journal-title":"Anal Chem"},{"issue":"11","key":"10.1002\/jps.24421_bb0115","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1107\/S0567740882010450","article-title":"Structure of the antiinflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1[lambda]6,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam)","volume":"38","author":"Kojic-Prodic","year":"1982","journal-title":"Acta Crystallogr Sect B"},{"key":"10.1002\/jps.24421_bb0120","first-page":"13","article-title":"Physico-chemical and analytical characteris-tics of piroxicam","volume":"32","author":"Mihali\u0107","year":"1982","journal-title":"Acta Pharm Jugosl"},{"key":"10.1002\/jps.24421_bb0125","series-title":"Analytical profiles of drug substances","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0099-5428(08)60422-0","article-title":"Piroxicam","author":"Mihali\u0107","year":"1986"},{"issue":"7","key":"10.1002\/jps.24421_bb0130","first-page":"477","article-title":"X-ray studies on piroxicam modifications","volume":"43","author":"Reck","year":"1988","journal-title":"Die Pharmazie"},{"issue":"4","key":"10.1002\/jps.24421_bb0135","first-page":"257","article-title":"Prediction and establishment of a new crystalline piroxicam modification","volume":"45","author":"Reck","year":"1990","journal-title":"Pharmazie"},{"issue":"1-3","key":"10.1002\/jps.24421_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-5173(91)90124-7","article-title":"Investigation of piroxicam polymorphism","volume":"68","author":"Vre\u010der","year":"1991","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1002\/jps.24421_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(03)00057-7","article-title":"Characterization of piroxicam crystal modifications","volume":"256","author":"Vre\u010der","year":"2003","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1002\/jps.24421_bb0150","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/cg049876y","article-title":"Polymorphism in piroxicam","volume":"4","author":"Sheth","year":"2004","journal-title":"Cryst Growth Des"},{"issue":"11","key":"10.1002\/jps.24421_bb0155","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1002\/jps.23287","article-title":"Complementing high-throughput X-ray powder diffraction data with quantum-chemical calculations: Application to piroxicam form III","volume":"101","author":"Naelap\u00e4\u00e4","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1002\/jps.24421_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ssnmr.2006.02.003","article-title":"14N nuclear quadrupole resonance of some sulfa drugs","volume":"30","author":"Blinc","year":"2006","journal-title":"Solid State Nucl Magn Reson"},{"issue":"1","key":"10.1002\/jps.24421_bb0165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.chemphys.2006.10.004","article-title":"14N nuclear quadrupole resonance of picolinic, nicotinic, isonicotinic and dinicotinic acids","volume":"331","author":"Seliger","year":"2006","journal-title":"Chem Phys"},{"issue":"8","key":"10.1002\/jps.24421_bb0170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1063\/1.1716296","article-title":"Modified spin-echo method for measuring nuclear relaxation times","volume":"29","author":"Meiboom","year":"1958","journal-title":"Rev Sci Instrum"},{"issue":"7","key":"10.1002\/jps.24421_bb0175","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1063\/1.435286","article-title":"Multiple spin echoes in pure quadrupole resonance","volume":"67","author":"Marino","year":"1977","journal-title":"J Chem Phys"},{"issue":"5-6","key":"10.1002\/jps.24421_bb0180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0375-9601(03)00207-X","article-title":"Multiple NQR spin echoes in phase cycled pulse experiments","volume":"309","author":"Rudakov","year":"2003","journal-title":"Phys Lett A"},{"issue":"3","key":"10.1002\/jps.24421_bb0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1103\/PhysRev.94.630","article-title":"Effects of diffusion on free precession in nuclear magnetic resonance experiments","volume":"94","author":"Carr","year":"1954","journal-title":"Phys Rev"},{"issue":"1-2","key":"10.1002\/jps.24421_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2012.03.008","article-title":"Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling","volume":"429","author":"Naelap\u00e4\u00e4","year":"2012","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1002\/jps.24421_bb0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/1097-0282(2001)62:1<68::AID-BIP80>3.0.CO;2-X","article-title":"Influence of environment on piroxicam polymorphism: Vibrational spectroscopic study","volume":"62","author":"Taddei","year":"2001","journal-title":"Biopolymers"},{"issue":"4","key":"10.1002\/jps.24421_bb0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejps.2004.11.010","article-title":"Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam","volume":"24","author":"Cilurzo","year":"2005","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1002\/jps.24421_bb0205","first-page":"89","article-title":"Preparation and characterization of microparticles of piroxicam by spray drying and spray chilling methods","volume":"5","author":"Dixit","year":"2010","journal-title":"Res Pharm Sci"},{"issue":"4","key":"10.1002\/jps.24421_bb0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11094-008-0091-0","article-title":"Compatibility studies between piroxicam and pharmaceutical excipients used in solid dosage forms","volume":"42","author":"Stulzer","year":"2008","journal-title":"Pharm Chem J"},{"issue":"4","key":"10.1002\/jps.24421_bb0215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.polymertesting.2013.03.004","article-title":"Structural analysis of insulating polymer foams with THz spectroscopy and imaging","volume":"32","author":"Abina","year":"2013","journal-title":"Polym Test"},{"issue":"12","key":"10.1002\/jps.24421_bb0220","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/jps.20191","article-title":"Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure","volume":"93","author":"Sheth","year":"2004","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T09:24:21Z","timestamp":1537781061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915300769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0022354915300769"],"URL":"https:\/\/doi.org\/10.1002\/jps.24421","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}